OTCMKTS:GSGTF GenSight Biologics (GSGTF) Stock Price, News & Analysis $0.24 0.00 (0.00%) As of 07/14/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About GenSight Biologics Stock (OTCMKTS:GSGTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GenSight Biologics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2450-Day Range$0.24▼$0.2452-Week Range$0.32▼$0.32VolumeN/AAverage Volume583 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GenSight Biologics (OTCMKTS: GSGTF) is a clinical‐stage biopharmaceutical company specializing in the development of gene therapies for retinal and central nervous system diseases. The company leverages mitochondrial and optogenetic platforms to address unmet medical needs in vision loss and neurodegenerative conditions. Its pipeline focuses primarily on therapies designed to restore or preserve vision in patients suffering from Leber hereditary optic neuropathy (LHON) and age-related macular degeneration (AMD). Founded in 2012 and headquartered in Paris, France, GenSight Biologics conducts research and clinical development across Europe and the United States. Its lead product candidate, LUMEVOQ, is an AAV‐based gene therapy intended to treat LHON caused by the ND4 mitochondrial DNA mutation. Additionally, GenSight is advancing GS030, an optogenetic therapy aimed at reactivating retinal cells in dry AMD patients. Both programs have progressed through early‐phase clinical trials, with ongoing studies evaluating safety, tolerability and visual function outcomes. GenSight Biologics is led by Chief Executive Officer Bernard Gilly, who co‐founded the company to translate pioneering gene therapy science into potential treatments for blinding diseases. The management team combines expertise in ophthalmology, mitochondrial biology and clinical development, supporting collaborations with academic institutions and research hospitals. Through its dedicated vertically integrated R&D model, GenSight aims to bring first‐in‐class therapies to patients affected by inherited and degenerative eye disorders.AI Generated. May Contain Errors. Read More Receive GSGTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenSight Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address GSGTF Stock News HeadlinesGenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene TherapyJuly 18 at 10:27 AM | finance.yahoo.comGenSight Biologics Reports Cash Position as of June 30, 2025July 8, 2025 | businesswire.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 18 at 2:00 AM | Timothy Sykes (Ad)GSGTF | GenSight Biologics S.A. Stock Overview (U.S.: OTC) - Barron'sJune 29, 2025 | barrons.comGenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in FranceJune 12, 2025 | businesswire.comGenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025May 13, 2025 | businesswire.comGenSight Biologics SA (G49N) Gets a Hold from Kepler CapitalApril 10, 2025 | markets.businessinsider.comGenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business UpdateApril 7, 2025 | businesswire.comSee More Headlines GSGTF Stock Analysis - Frequently Asked Questions How have GSGTF shares performed this year? GenSight Biologics' stock was trading at $0.24 at the start of the year. Since then, GSGTF shares have increased by 0.0% and is now trading at $0.24. How do I buy shares of GenSight Biologics? Shares of GSGTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/18/2025Next Earnings (Estimated)9/19/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:GSGTF CIKN/A Webwww.gensight-biologics.com Phone(317) 621-7220FaxN/AEmployees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (OTCMKTS:GSGTF) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenSight Biologics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share GenSight Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.